Reviewing Vivos Therapeutics (NASDAQ:VVOS) & Biostage (OTCMKTS:BSTG)

Vivos Therapeutics (NASDAQ:VVOS) and Biostage (OTCMKTS:BSTG) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, dividends and analyst recommendations.

Risk & Volatility

Vivos Therapeutics has a beta of 7.47, meaning that its stock price is 647% more volatile than the S&P 500. Comparatively, Biostage has a beta of -1.02, meaning that its stock price is 202% less volatile than the S&P 500.

Profitability

This table compares Vivos Therapeutics and Biostage’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vivos Therapeutics	-86.19%	-335.04%	-93.58%
Biostage	N/A	N/A	-174.43%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Vivos Therapeutics and Biostage, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivos Therapeutics	0	0	2	0	3.00
Biostage	0	0	0	0	0.00

Vivos Therapeutics presently has a consensus target price of $6.30, indicating a potential upside of 90.33%. Given Vivos Therapeutics’ stronger consensus rating and higher possible upside, equities analysts plainly believe Vivos Therapeutics is more favorable than Biostage.

Insider & Institutional Ownership

26.4% of Vivos Therapeutics shares are owned by institutional investors. 3.0% of Vivos Therapeutics shares are owned by insiders. Comparatively, 15.3% of Biostage shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Vivos Therapeutics and Biostage”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivos Therapeutics	$13.80 million	1.41	-$13.58 million	($5.68)	-0.58
Biostage	N/A	N/A	-$6.07 million	($0.58)	-7.67

Biostage has lower revenue, but higher earnings than Vivos Therapeutics. Biostage is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Vivos Therapeutics beats Biostage on 8 of the 13 factors compared between the two stocks.

About Vivos Therapeutics

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.

About Biostage

Biostage, Inc., a biotechnology company, offers products to cure patients of cancers, injuries, and birth defects of the gastro-intestinal tract and the airways. The company's pipeline includes organ-regeneration technology for the repair or replacement of diseased or damaged organs, as well as product candidates to treat cancer, injury, and birth defects of the bronchus. Its lead product candidate is Biostage Esophageal Implant for the treatment of severe esophageal disease. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2009 and is headquartered in Holliston, Massachusetts.